KLOW
Multi peptide
ABOUT
KLOW is a vendor-assembled four-peptide blend sold as a single 80 mg lyophilised vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. It is not a licensed product and has no literature of its own.
WHAT IS IN IT · 4 COMPOUNDS
Check the amounts on the vial rather than assuming them from the blend name.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Four separate mechanisms in one vial rather than one combined mechanism. GHK-Cu is a copper-binding tripeptide studied for effects on collagen and gene expression; BPC-157 is a synthetic gastric-juice-derived pentadecapeptide credited with angiogenic and cytoprotective activity in rodents; TB-500 is a fragment of the actin-sequestering protein thymosin beta-4; KPV is the C-terminal tripeptide of alpha-MSH with anti-inflammatory activity that does not require melanocortin-receptor binding. The blend rests on the assumption that four repair-adjacent mechanisms add up, which no source demonstrates.
PHARMACOKINETICS
None of the four components has a published human pharmacokinetic profile, so the blend has none either. The fixed 5:1:1:1 mass ratio is a manufacturing decision, not a ratio derived from any exposure or dose-finding study.
REVIEW
PUBLISHED PAIR RECORDS
with GHK-Cu
Same substance taken twice: blend already contains this compoundKLOW already contains GHK-Cu at 50 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with BPC-157
Same substance taken twice: blend already contains this compoundKLOW already contains BPC-157 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with TB-500
Same substance taken twice: blend already contains this compoundKLOW already contains TB-500 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with KPV
Same substance taken twice: blend already contains this compoundKLOW already contains KPV at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GLOW
Overlapping blends: the same compounds appear in bothKLOW and GLOW both contain GHK-Cu, BPC-157, TB-500. Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Wolverine blend
Overlapping blends: the same compounds appear in bothKLOW and Wolverine blend both contain BPC-157, TB-500. Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Thymosin Beta-4
Inherited from a component of this blendKLOW contains BPC-157 and TB-500, and the catalogue holds a curated pair record between those components and Thymosin Beta-4: BPC-157 (commonly combined tissue-repair peptides with no combination evidence); TB-500 (same molecule family: fragment and parent protein). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
No study has examined this blend as a blend. A PubMed search for the product name returns no matching literature, so everything known about it is inference from its separate components, and the effect of giving them together at a fixed ratio is uncharacterised rather than known to be additive. The strongest human evidence behind any component is a single uncontrolled retrospective chart review of BPC-157 in knee pain, and a small negative cosmetic study of topical GHK-Cu. GHK-Cu here is injected, which is a different exposure from the topical route its one controlled human study used.
REPORTED EFFECTS
No safety data exists for the blend. Component-level regulatory status carries over: BPC-157 and thymosin beta-4 fragments sit on FDA's Category 2 interim compounding list, KPV was added to it in September 2023, and injectable-route GHK-Cu is also listed there while non-injectable use is not. Thymosin beta-4 and its derivatives are prohibited at all times in sport. Material sold this way is not made to a pharmacy purity standard, and a single vial multiplies that exposure across four substances.
RESEARCH LIMITATIONS
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CURATED SOURCES · 6